Arbutus Biopharma Corp. (ABUS)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1447028 · fiscal year ends in Dec
Closing price $4.28 on 29 Oct 2026; 52-week range $3.67 to $5.22.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $181.7M
- Revenue growth
- 1078.8%
- Net income, last twelve months
- $153.1M
- Earnings per share
- $0.79
- Operating margin
- 82.0%
- Net margin
- 84.2%
- Return on equity
- 59.2%
- Market value
- $845.9M
- Price to earnings
- 5.4x
- Cash
- $19.2M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 197.6M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $14.1M | -$38.2M | -$33.5M | -$0.17 | -$39.6M | 10-K filed 23 Mar 2026 |
| FY2024 | 31 Dec 2024 | $6.2M | -$76.3M | -$69.9M | -$0.38 | -$65.0M | 10-K filed 27 Mar 2025 |
| FY2023 | 31 Dec 2023 | $18.1M | -$78.1M | -$72.8M | -$0.44 | -$86.9M | 10-K filed 5 Mar 2024 |
| FY2022 | 31 Dec 2022 | $39.0M | -$65.5M | -$69.5M | -$0.46 | -$35.9M | 10-K filed 2 Mar 2023 |
| FY2021 | 31 Dec 2021 | $11.0M | -$73.5M | -$76.2M | -$0.83 | -$68.3M | 10-K filed 3 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $1.0M | -$5.1M | -$0.03 |
| Q1 FY2026 | 31 Mar 2026 | $179.1M | $169.7M | $0.87 |
| Q4 FY2025 | 31 Dec 2025 | $1.1M | -$3.8M | -$0.01 |
| Q3 FY2025 | 30 Sep 2025 | $529.0K | -$7.7M | -$0.04 |
| Q2 FY2025 | 30 Jun 2025 | $10.7M | $2.5M | $0.01 |
| Q1 FY2025 | 31 Mar 2025 | $1.8M | -$24.5M | -$0.13 |
| Q4 FY2024 | 31 Dec 2024 | $1.6M | -$12.5M | -$0.07 |
| Q3 FY2024 | 30 Sep 2024 | $1.3M | -$19.7M | -$0.10 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Collaborations and licenses | $12.6M | 89.5% |
| Non-cash royalty revenue | $1.5M | 10.5% |
Company events
The newest 8-K filings of 312 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 22 Oct 2026 | 8-K | Other events | 8.01, 9.01 |
| 21 Aug 2026 | 8-K | Other events | 8.01, 9.01 |
| 12 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 16 Jul 2026 | 8-K | Leadership change, Agreement ended, Other events | 1.02, 5.02, 8.01, 9.01 |
| 27 May 2026 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07, 9.01 |
| 13 May 2026 | 8-K | Results | 2.02, 9.01 |
| 15 Apr 2026 | 8-K | Other events | 8.01, 9.01 |
| 23 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 3 Mar 2026 | 8-K | Material agreement, Other events | 1.01, 8.01, 9.01 |
| 20 Feb 2026 | 8-K | Other events | 8.01, 9.01 |
| 6 Feb 2026 | 8-K | Other events | 8.01, 9.01 |
| 16 Jan 2026 | 8-K | Other events | 8.01, 9.01 |
Every filing
The newest filings with the SEC of 642 held.
| Filed | Form | Period |
|---|---|---|
| 22 Oct 2026 | 8-K | 20 Oct 2026 |
| 1 Oct 2026 | SC TO-I/A | – |
| 30 Sep 2026 | SC TO-I/A | – |
| 24 Aug 2026 | SC TO-I | – |
| 21 Aug 2026 | SC TO-C | – |
| 21 Aug 2026 | 8-K | 21 Aug 2026 |
| 12 Aug 2026 | 10-Q | 30 Jun 2026 |
| 12 Aug 2026 | 8-K | 12 Aug 2026 |
| 16 Jul 2026 | 8-K | 15 Jul 2026 |
| 5 Jun 2026 | S-8 | – |
| 27 May 2026 | 8-K | 26 May 2026 |
| 13 May 2026 | 10-Q | 31 Mar 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 27 Oct 2026 | BlackRock, Inc. | 13G amended | 7.2% | 14.3M |
| 7 Oct 2026 | Morgan Stanley | 13G amended | 12.2% | 18.7M |
| 5 Oct 2026 | Roivant Sciences Ltd. | 13D amended | 19.5% | 29.9M |
| 4 Sep 2026 | Whitefort Capital Master Fund, LP | 13G | 8% | 15.8M |
| 12 Aug 2026 | Morgan Stanley | 13G amended | 8.8% | 17.4M |
| 15 May 2026 | Two Seas Capital LP | 13G amended | 9.4% | 18.6M |
| 28 Apr 2026 | Whitefort Capital Master Fund, LP | 13D amended | 8% | 15.8M |
| 13 Apr 2026 | Whitefort Capital Master Fund, LP | 13D amended | 8.1% | 15.8M |
| 17 Feb 2026 | Two Seas Capital LP | 13G amended | 6.5% | 12.6M |
| 11 Feb 2026 | Morgan Stanley | 13G amended | 13.5% | 25.9M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 24.6M | -27.86% | 4.34 |
| 30 Sep 2026 | 34.1M | +84.22% | 3.53 |
| 15 Sep 2026 | 18.5M | -2.28% | 5.01 |
| 31 Aug 2026 | 18.9M | +2.49% | 3.08 |
| 14 Aug 2026 | 18.5M | -8.8% | 15.1 |
| 31 Jul 2026 | 20.2M | +2.97% | 13.69 |
| 15 Jul 2026 | 19.7M | +14.85% | 7.4 |
| 30 Jun 2026 | 17.1M | -2.35% | 4.89 |
Funds that hold it
From each fund's latest Form 13F.
199 funds held it at 30 Jun 2026: 95 added and 40 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Two Seas Capital LP | 19,095,583 | $91.7M | +538,040 |
| Morgan Stanley | 17,698,305 | $85.0M | -8,193,175 |
| Whitefort Capital Management, LP | 15,794,261 | $75.8M | +863,376 |
| BlackRock, Inc. | 13,766,071 | $66.1M | +799,125 |
| State Street Corp. | 7,869,179 | $37.8M | +1,526,669 |
| Rubric Capital Management LP | 7,532,937 | $36.2M | +906,548 |
| Vanguard Capital Management LLC | 7,010,679 | $33.7M | +321,768 |
| Barclays PLC | 4,207,914 | $20.2M | -108,181 |
| Geode Capital Management, LLC | 4,117,691 | $19.8M | +345,885 |
| Goldman Sachs Group Inc. | 3,506,802 | $16.8M | +2,406,368 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B